Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Karen Eves

2PUBLICATIONS

13CO-AUTHORS

Pharmacogenomics

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (2)

Sort by Publication Date:

|May 29, 2026

Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA.

|Mar 13, 2025

Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial.

Jürgen K Rockstroh, Roger Paredes, Pedro Cahn

Pageof 1

Frequent Collaborators

2 joint publications

Stephanie O Klopfer

1 joint publications

Jürgen K Rockstroh

1 joint publications

Roger Paredes

1 joint publications

Pedro Cahn

1 joint publications

Simiso M Sokhela

1 joint publications

Federico Hinestrosa

1 joint publications

Sheetal Kassim

1 joint publications

Jade Ghosn

1 joint publications

Hiroyuki Gatanaga

1 joint publications

Ying Zhang

Frequent Collaborators

2 joint publications

Stephanie O Klopfer

1 joint publications

Jürgen K Rockstroh

1 joint publications

Roger Paredes

1 joint publications

Pedro Cahn